P latelet-rich plasma (PRP) is created through concentrating platelets found in whole blood. 1 It can aid in tissue regeneration, bone regeneration, and wound repair. [2] [3] [4] [5] [6] [7] Platelet-rich plasma treatment has also been suggested to promote hair growth, encourage cell survival and proliferation, and prolong the anagen phase of the hair cycle. [8] [9] [10] [11] [12] [13] Platelet-rich plasma is thought to exert its effects in androgenetic alopecia (AGA) via delivery of concentrated growth factors to the hair follicle and surrounding area ( Figure 1 ). Emerging evidence has begun to characterize the dermal and follicular response to several growth factors (e.g., platelet-derived growth factor, transforming growth factor beta). [14] [15] [16] [17] The main objective of this article was to assess the effectiveness of PRP as a monotherapy and adjunct treatment for male AGA.
Platelet-Rich Plasma as a Monotherapy for Male Androgenetic Alopecia
To analyze the effectiveness of PRP for the treatment of AGA, a meta-analysis was undertaken. A literature search was conducted using PubMed on September 7, 2017 and updated on May 18, 2018 . The following terms were used; "PRP,""hair,""platelet-rich plasma,""hair transplant,""hair loss,""androgenetic alopecia," and "alopecia." Studies were included if they evaluated the success of PRP for treatment of AGA using hair density (hairs/cm 2 ). [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Studies were excluded if they did not use direct injection, contained less than 5 participants per treatment, included only female participants, patients used alternative treatments (5a-reductase inhibitors, minoxidil) within 6 months of study start or if insufficient data were provided. Study parameters are listed in Table 1 with characteristics such as a larger patient population and use of controls, comparators, randomization, and blinding generally considered more scientifically rigorous. The meta-analysis was conducted using RevMan 5.3 (Copenhagen, Denmark). Effect size was measured through use of the standardized mean difference (SMD), where treatment versus comparator results close to 0 suggest no difference and increasingly higher scores are associated with improvement. Heterogeneity was evaluated using the I 2 statistic. 28, 29 The reported efficacy was compared to baseline measures, and a p-value < .05 was considered significant. The SMD in hair density was 0.58 (95% confidence interval [CI]: 0.35-0.80) in favor of PRP treatment (10 Figure 1 . Mechanism of action. Platelet-rich plasma is prepared from an autologous blood sample that is subsequently centrifuged to concentrate platelets. Platelet-rich plasma is then activated, often with the addition of calcium chloride to stimulate the release of growth factors. Platelet-rich plasma is subsequently injected into the patient's scalp, where various growth factors are thought to stimulate gene upregulation associated with angiogenesis, cell survival, and proliferation. AKT, protein kinase B; EGF, epidermal growth factor; ERK, extracellular signal-regulated kinase; FGF-7, fibroblast growth factor 7; IGF-1, insulin-like growth factor 1; mTOR, mechanistic target of rapamycin; PI3K, phosphoinositide 3-kinase; TGFb, transforming growth factor beta; TGFbRI, abrogated transforming growth factor beta receptor I; TGFbRII, abrogated transforming growth factor beta receptor II; VEGF, vascular endothelial growth factor; smad2, mothers against decapentaplegic homolog 2; smad3, mothers against decapentaplegic homolog 3. GUPTA ET AL 00:00:MONTH 2019 3 studies, pooled N = 165, p < .00001) (Figure 2A ). This result is consistent with a previously published metaanalysis that also favored PRP over baseline (SMD: 0.51, 95% CI: 0.14-0.88, p = .006). 30 Likewise, PRP exhibited a greater efficacy over placebo treatments (SMD: 0.51, 95% CI: 0.23-0.80, p < .0004) with the inclusion of 6 trials (pooled N = 99) 18, [22] [23] [24] 26, 27 ( Figure 2B ).
In this study, interestingly, and similar to some of the observations from previous research, 31 evidence for investigating male and female patients separately was found. Inclusion of an all-female study 32 in the current meta-analysis (otherwise composed of all male and mostly male studies) was not possible due to an introduction of high heterogeneity (measured I 2 = 89%), leading to the suggestion that female patients should be investigated distinctly. This idea has practical implications for clinicians as there are few AGA treatment options for female patients and encourages new research directions to test this hypothesis with the possibility of creating a unique PRP protocol targeted directly to female patients.
Investigating methods across AGA studies, with the exception of a few minor modifications, only 2 PRP protocols were duplicated. 33, 34 Both studies reported that subjects treated with PRP had a greater change in hair density compared to placebo-treated subjects. Khatu and colleagues and Singhal and colleagues both used an activated (calcium chloride) PRP treatment (2-week interval between sessions, 4 sessions total) created using a double spin technique (1,500 rpm for 6 minutes and 2,500 rpm for 15 minutes). 33, 34 These 2 studies did differ in how much PRP was injected; 2 to 3 mL per injection versus 8 to 12 mL per injection. 33, 34 Cervelli and colleagues and Gentile and colleagues also used a similar protocol, administering PRP (0.1 mL/cm 2 per injection) every 4 weeks for a total of 3 sessions. 22, 35 Both studies used the Cascade-SelphylEsforax system, centrifuging the PRP solution at 1,100g for 10 minutes. 22, 35 Cervelli and colleagues and Gentile and colleagues reported that PRP-treated patients had a significantly greater mean change in hair density as compared to placebo-treated patients (both studies p < .0001). 22, 35 Overall, the results suggest that PRP therapy resulted in a significantly greater increase Use of a closed system is recommended for patient safety and reproducibility 24 Examples of collection systems that are FDA approved (510k clearance) include the Arthex Angel System, 41 Biomet GPS III, 42 Eclipse PRP system, 43 Emcyte PurePRP Genesis CS concentrating device, 44 Harvest SmartPrep, 45 Magellan TruPRPä, 46 RegenKit Blood Cell Therapy, 47 and the Selphyl system 48 Each system incorporates its own feature such as an agar plug that may facilitate a high-volume PRP yield in the Eclipse PRP system, 49 the compartmentalized reservoir bag that enables different mediums (whole blood or mixture of blood and bone marrow) to be separated through centrifugation in the Arthex Angel System, 50 and the use of calcium chloride in the Selphyl System to enhance delivery of growth factors through fibrin matrices created by the conversion of fibrinogen to fibrin 51 Each collection system also varies in growth factor and cytokine concentrations, platelet capture efficiencies, and resulting monocyte populations 23, 38, 39 A high platelet recovery rate, elevated growth factor and cytokine concentrations, and a low red blood cell count is desired
The optimum platelet concentration has been shown to be 1.5 million per microliter (about 5-fold more concentrated than the normal range of 150,000-400,000), 52 although currently there are no in vivo studies that compare results for hair growth directly Centrifugation and sonication
During centrifugation, high speeds and long durations can inadvertently precipitate platelets or discharge growth factors (e.g., platelet-derived growth factor), influencing the efficacy of PRP 53, 54 As a potential alternative to centrifugation, acoustic-based particle manipulation methods could be used to separate blood cells 55 Sonication can lyse platelet cell membranes, allowing the release of growth factors and be more effective in separation of red and white blood cells 56 Ultrasound-generated PRP demonstrated a greater platelet recovery rate as compared to PRP obtained through centrifugation (79 6 9% vs 54 6 10% over baseline, respectively) 56 Sonication may increase the survival rate of transplanted follicular units 57 Activation Activation using calcium chloride or calcium gluconate is frequently used in hair loss studies to induce a granule release of growth factors from platelets 18, 23, 25, [32] [33] [34] [58] [59] [60] [61] Extracellular matrix materials such as ACell (FDA approved to repair and remodel damaged tissue) could also be used to activate PRP solutions, although current evidence for this technique remains anecdotal Alternatively, microparticles could be a functional and cheaper substitute 62, 63 The combination of microparticles, adipose derived stem cells, and follicular stem cells could also be advantageous and are currently under investigation Scalp needling to induce inflammation leading to platelet activation has been suggested to be as effective as use of an exogenous activator 64 Similarly, it has been suggested that exogenous activation may not make a significant impact on specific growth factors and cytokines, such as platelet-derived growth factor BB and transforming growth factor b1, 23 although a direct comparison (n = 40) of nonactivated versus calcium chlorideactivated PRP resulted in significantly more effective treatment in the former 40 Thus, although it is clear that activation is necessary for growth factor release, further research is necessary to determine the impact of various methods of activation on the efficacy of PRP Injection depth Follicles vary in length below the skin surface, averaging 4.2 mm in length 65 Subdermal injections have been shown to be efficacious and tolerable in a blinded randomized clinical trial (n = 40) 66 ; success has been found with intradermal injections, injections into recipient slits during transplantation, and injections into microneedling channels 54, 67 Use of a mechanical and thus reproducible device has also been recommended for controlled delivery of PRP 24 GUPTA ET AL 00:00:MONTH 2019 5 in hair density compared to baseline counts and placebo.
There are a number of factors that could explain the variation seen in PRP results (Table 2 ). Differences in preparations and delivery have been suggested as a possible explanation. 36, 37 In addition to platelet concentration, white blood cell, neutrophil, and red blood cell concentration varies with separation systems as well. 38, 39 The resulting effect on efficacy is unknown; however, individual advantages are expected with the various systems. 38 For example, in direct comparison (n = 6), the Arthex Angel System resulted in significantly improved hair density versus the Regen Cell Therapy collection system. 23 Patient characteristics may also influence the results of PRP treatment (Table 3) . Variables from each study (Table 4) were examined using a chi squared analysis and Fisher exact test to identify any protocol trends that led to significant results more often than expected. Specifically, each variable (population demographics, centrifuge process, concentration of platelets, injection process, needle gauge, method of platelet activation, quantity and intervals of treatment, and time of analysis) was examined in search 68 Substantial improvements in hair restoration parameters (e.g., hair density, hair count) have frequently been reported in PRP studies that administer 3 monthly sessions, suggesting that 3 sessions may be necessary to achieve desired results 18, [22] [23] [24] 35, 60, 61 A 3-to 6-mo maintenance interval after a monthly PRP treatment regimen could be beneficial 69 Follow-up periods should extend to 12 mo post-treatment, as an early decrease in hair density coinciding with the PRP-driven stimulation of hairs into the anagen stage is expected AGA, androgenetic alopecia; FDA, Food and Drug Administration; PRP, platelet-rich plasma.
TABLE 3. Factors That Could Influence the Efficacy of Platelet-Rich Plasma

Patient Characteristics Evidence
Gender Male patients experienced new growth 2 wk earlier and had a higher increase in hair counts in comparison to the female population (n = 115) 31 Statistically significant increase in the mean total hair density for male patients in comparison to female patients (n = 25) 18 Severity of alopecia Significantly better response from patients with a lower grade of alopecia (Grade III-IV alopecia, Hamilton-Norwood) 21, 25, 53, 59, 70 Disease duration Most studies observed a significantly better response from patients with a shorter disease duration 21, 53, 59 Alves and Grimalt 18 observed a statistically significant increase in the mean total hair density in patients with greater than 10 years of disease duration
Age
Alves and Grimalt 18 observed a statistically significant increase in the mean total hair density for patients younger than 40 years Borhan and colleagues 21 observed the best response in patients in their early 30s
Onset of alopecia Alves and Grimalt 18 observed a statistically significant increase in the mean total hair density for patients with hair loss beginning after 25 years
Presence of vellus hair
Presence of vellus hair led to better results compared to those who had few but normal hair 25, 70 PRP PROTOCOL RECOMMENDATIONS DERMATOLOGIC SURGERY 6 GUPTA ET AL 00:00:MONTH 2019 9 of a similar variable appearing more often than by random probability in the protocols of studies which achieved statistically significant results. The use of an exogenous activator appeared the most connected to achieving desirable results (p = .08) that was similar to the conclusions of an earlier meta-analysis. 30 Nonetheless, this suggestion contrasts a direct comparison of nonactivated versus calcium chlorideactivated treatments (n = 40), which concluded the former to be significantly more effective. 40 From this analysis combined with the results of the metaanalysis (above), specific PRP techniques and methods are recommended (Table 5) .
Conclusions
Platelet-rich plasma could be used to improve hair restoration parameters (e.g., hair density) in AGA monotherapy or adjunct therapy. For the former, 3 sessions of PRP at 1-month intervals followed by a maintenance regimen is recommended. 
